BioSpace News Archive

Intellia Therapeutics and Regeneron Pharmaceuticals presented positive interim data from an ongoing Phase I trial of NTLA-2001 for transthyretin (ATTR) amyloidosis.

Amryt Pharma is filing a formal dispute resolution request (FDRR) with the FDA after receiving a CRL that delays the production of its drug for a rare skin disorder.

While it was a relatively quiet week for clinical trial announcements overall, BioSpace takes a look at some of the more intriguing ones.

The genetically-modified heart of a man who died two months after his heart was replaced with that of a pig had nearly doubled in size, autopsy results show.

Talks between Merck and Seagen are heating up as the former looks to buy the latter, according to a report published by The Wall Street Journal.

argenx announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended European Commission approval of efgartigimod as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.

Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces the appointment of Anja Krammer and August Moretti as members of the company’s Board of Directors.

ValnevaSE, a specialty vaccine company, announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting held yesterday in Paris.

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced that the Board of Directors has named Hilde Windels as Chairwoman of the Board of Directors, effective immediately.

Kinarus Therapeutics Holding AG announced that it will host a key opinion leader event for investors in Zurich on Monday, June 27, starting at 12:15 pm CET.